• Jingjie Wu, Yao Wei, Yaoxin Chen, Yu Long, Nierui Huang, and Yingbing Mei.
• Shanghai Jinshan TCM-integrated Hospital, Shanghai, China.
• Medicine (Baltimore). 2021 Nov 24; 100 (47): e27761e27761.

BackgroundIn recent years, many clinical studies have suggested that various Chinese patent medicines have the potential to treat functional dyspepsia (FD). This study aims to conduct a systematic review and Bayesian network meta-analysis to evaluate the effectiveness of different Chinese patent medicines for FD.MethodsA comprehensive retrieval method will be executed in the following databases: PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBM), VIP Database, and Wanfang Database. Clinical randomized controlled trials (RCTs) of 9 Chinese patent medicines for FD are searched, and the retrieval time is from inception to October 2021. Three reviewers will screen the RCTs that meet the inclusion criteria and extract the data independently. The outcomes include total clinical efficiency, cure rate, recurrence rate, symptom score, and adverse events. Cochrane risk-of-bias tool will be carried to assess RCTs quality. The "gemtc" package and "rjags" package in R software will be used to manage data within the Bayesian framework.ResultsThe results can provide relatively objective evidence to evaluate the effectiveness of these 9 Chinese patent medicines in treating FD, which may help clinicians to develop a more effective and safer treatment plan.ConclusionThis study aims to provide new options for Chinese patent medicine treatment of FD in terms of its efficacy and safety.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

23 keywords...

hide…